袁胜涛研究员个人简介

  

 

    袁胜涛,药理学博士,研究员

 

    1996年获上海医科大学病理专业硕士学位;1998年-2001年师从中国科学院上海药物研究所丁健院士,获肿瘤药理博士学位,攻读博士学位期间主要研究沙尔威辛体内抗肿瘤作用和抗转移作用;2002年赴芬兰赫尔辛基大学做访问学者,研究植物来源的化合物对间质基质金属蛋白酶的抑制作用。

 

    申请人长期从事肿瘤药理和新药研究开发工作,具有丰富的抗肿瘤药物研发经验及扎实的理论基础。主持国家自然基金“YS-1抗肿瘤转移作用及分子机制研究”(编号:81071841),国家自然科学基金“沙尔威辛的抗转移作用及其分子机制的研究”(项目编号:30200324);作为项目副组长主持了江苏省药效研究与评价服务中心资助项目(编号:BK2006150),并于2009年通过江苏省科技厅的验收;作为主要成员参与了国家“十一五”科技重大专项“新药筛选平台”(编号:2009ZX09302-002);国家“十五”重大专项“新药筛选平台技术研究”(编号:2002AA2Z343E);国家“十五”重大专项“新型高通量筛选模型、化合物库建设和药物筛选”(编号:2004AA2Z3785);等项目的研究工作。2006年获得江苏省科技进步一等奖,《新型药物筛选体系的研究与应用》。

    主要研究方向:一是针对肿瘤的发生发展及转移进行相关机制研究,着眼于肿瘤微环境在肿瘤转移中的作用研究,并在此基础上开展高通量药物筛选工作,发现可用于进一步开发的先导化合物或药物候选物,为新药发现提供物质基础;二是抗肿瘤药物评价,与国内外多家知名企业合作,进行抗肿瘤药物研发。

 

发表论文:
(1) Gao M, Li X, Dong W, Jin R, Ma H, Yang P, Hu M, Li Y, Hao Y, Yuan S, Huang J, Song L.Ribosomal protein S7 regulates arsenite-induced GADD45α expression by attenuating MDM2-mediated GADD45α ubiquitination and degradation.Nucleic Acids Res. 2013 Apr 5. [Epub ahead of print]
(2)Sun L, Liu Y, Lin S, Shang J, Liu J, Li J, Yuan S, Zhang L.Early growth response gene-1 and hypoxia-inducible factor-1α affect tumor metastasis via regulation of tissue factor. Acta Oncol. 2013 May;52(4):842-51.
(3)Zhao R, Sun L, Lin S, Bai X, Yu B, Yuan S, Zhang L.The saponin monomer of dwarf lilyturf tuber, DT-13, inhibits angiogenesis under hypoxia and normoxia via multi-targeting activity.Oncol Rep. 2013 Apr;29(4):1379-86.
(4)Dong W, Li Y, Li X, Hu M, Aodengqimuge, Sun L, Guo N, Yuan S, Song L.p85α mediates NFAT3-dependent VEGF induction in the cellular UVB response.J Cell Sci. 2013 Mar 15;126(Pt 6):1317-22.
(5) Fang D, Sun L, Lin S, Zhou L, Su N, Yuan S, Yu B.Vinorelbine inhibits angiogenesis and 95D migration via reducing hypoxic fibroblast stromal cell-derived factor 1 secretion. Exp Biol Med (Maywood). 2012 Sep 1;237(9):1045-55.
(6). Zhu J, Sun L, Lin S, Zhao R, Zhou L, Fang D, Chen L, Liu J, Shi W, Zhang L, Yuan S.BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells. J Exp Clin Cancer Res. 2012 Mar 31;31:313.
(7)Lin S, Wan S, Sun L, Hu J, Fang D, Zhao R, Yuan S, Zhang L.Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia. Cancer Sci. 2012 May;103(5):904-12.
(8). Koumtebarye E, Su N, Hu WF, Lin SS, Sun L,Yuan ST. Antitumor activity of Xiaoaiping injection on human gastric cancer SGC-7901 cells Chinese Journal of Natural Medicines 2012, 10(5): 339-346
(9) Zhou L, Sun L, Lin S, Fang D, Zhao R, Zhu J, Liu J, Chen L, Shi W, Yuan S*, Zhu D Inhibition of angiogenic activity of hypoxic fibroblast cell line MRC-5 in vitro by topotecan. Medical Oncology. DOI: 10.1007/s12032-010-9710-1. (2011).
(10) Li Sun, Sensen Lin, Renping Zhao, Boyang Yu, Shengtao Yuan*, and Luyong Zhang. The saponin monomer of dwarf lilyturf tuber, DT-13, reduces human breast cancer cell adhesion and migration during hypoxia via regulation of tissue factor. Biol. Pharm. Bull. 33(7) 1192-1198 (2010).
(11) SUN Li, LIN Sen-Sen, Yu Bo-Yang, YUAN Sheng-Tao*, ZHANG Lu-Yong.High-throughput screening model for tissue factor inhibitor and effect of DT-13 on anti-tumor metastasis. Chin J Nat Med. Nov. 2010 Vol. 8 No. 6 466-470.
(12) Sensen Lin, Li Sun, Jialiang Hu, Shuying Wan, Renping Zhao, Shengtao Yuan*, Luyong Zhang. Chemokine CXC motif receptor 6 contributes to cell migration during hypoxia Cancer Lett. 2009 Jun 28; 279(1):108-17.

(13) Sen-sen LIN, Li SUN, Yan-kai ZHANG, Ren-ping ZHAO, Wen-lu LIANG, Sheng-tao YUAN*, Lu-yong ZHANG. Topotecan inhibits cancer cell migration by down-regulation of chemokine CC motif receptor 7 and matrix metalloproteinases, Acta Pharmacologica Sinica. 2009 May; 30(5):628-36.

 

发明专利:
(1) 冬凌草甲素类衍生物、其制备方法及用途,公开号200710133915.X
(2) 一种沉香叶提取物及其医药和保健用途, 公开号200710019969.3
(3) 组织因子抑制剂高通量筛选模型,申请号:2008101564415
(4) 短葶山麦冬C在制药中的应用,已授权Zl2008 1 0196044.0

(5) 一种基因疫苗及其制备方法和在制药中的应用,专利号:200910026786.3